A Benefit-Risk Assessment of Agents Used in the Secondary Prevention of Stroke

ISSN： 0114-5916

Source： Drug Safety, Vol.25, Iss.13, 2002-01, pp. : 943-963

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Benefit-Risk Assessment of Class III Antiarrhythmic Agents

By Brendorp B.

Drug Safety, Vol. 25, Iss. 12, 2002-01 ,pp. : 847-865

Adis International

Access to resources Recommend Favorite

A benefit–risk assessment of class III antiarrhythmic agents

By Elming Hanne Brendorp Bente Pehrson Steen Pedersen Ole Dyg Køber Lars Torp-Petersen Christian

Expert Opinion on Drug Safety, Vol. 3, Iss. 6, 2004-11 ,pp. : 559-577

Informa Healthcare

Access to resources Recommend Favorite

Clinical Pharmacokinetics of Antiplatelet Agents Used in the Secondary Prevention of Stroke

By Lenz T.L. Wilson A.F.

Clinical Pharmacokinetics, Vol. 42, Iss. 10, 2003-01 ,pp. : 909-920

Adis International

Access to resources Recommend Favorite

A Benefit-Risk Assessment of Dabigatran in the Prevention of Venous Thromboembolism in Orthopaedic Surgery

By Schulman Sam Majeed Ammar

Drug Safety, Vol. 34, Iss. 6, 2011-06 ,pp. : 449-463

Adis International

Access to resources Recommend Favorite

A Risk-Benefit Assessment of the Newer Oral Antifungal Agents Used to Treat Onychomycosis

By Gupta A.K.

Drug Safety, Vol. 22, Iss. 1, 2000-01 ,pp. : 33-52

Adis International

Access to resources Recommend Favorite